HER2神经蛋白异质性的临床重要性。
The Clinical Importance of the Heterogeneity of HER2 neu.
作者信息
Davila Enrique, Amazon Kip
机构信息
Aventura Comprehensive Cancer Center, Aventura, Fla., USA.
出版信息
Case Rep Oncol. 2010 Jul 24;3(2):268-271. doi: 10.1159/000319020.
Abstract
We report on a patient with breast cancer in whom there were areas of the tumor that were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each other. Depending on the area tested the results were completely different. The clinical implications are important. We recommend retesting a large portion of the tumor in all cases of initially negative test results.
摘要
我们报告了一名乳腺癌患者，其肿瘤区域通过免疫组织化学检测，HER2 neu呈3+阳性和阴性，二者相邻。根据检测区域的不同，结果完全不同。其临床意义重大。我们建议对所有初始检测结果为阴性的病例重新检测肿瘤的大部分区域。
相似文献
1
The Clinical Importance of the Heterogeneity of HER2 neu.HER2神经蛋白异质性的临床重要性。
Case Rep Oncol. 2010 Jul 24;3(2):268-271. doi: 10.1159/000319020.
2
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.乳腺癌中HER2/neu的瘤内异质性——一种罕见情况。
Breast J. 2007 Mar-Apr;13(2):122-9. doi: 10.1111/j.1524-4741.2007.00396.x.
3
Chromogenic Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma.显色杂交技术与免疫组织化学在448例伊拉克浸润性乳腺癌患者HER2/neu状态评估中的比较
Open Access Maced J Med Sci. 2019 Jun 30;7(12):1917-1925. doi: 10.3889/oamjms.2019.342.
4
Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings.乳腺癌患者中HER2/neu癌基因的定量实时聚合酶链反应检测及免疫组化评估及其与临床病理结果的相关性
Indian J Pathol Microbiol. 2020 Feb;63(Supplement):S123-S128. doi: 10.4103/IJPM.IJPM_136_19.
5
Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.子宫内膜浆液性癌中 HER2/NEU 基因扩增存在显著异质性。
Genes Chromosomes Cancer. 2013 Dec;52(12):1178-86. doi: 10.1002/gcc.22113. Epub 2013 Oct 7.
6
FISH and HER2/ equivocal immunohistochemistry in breast carcinoma.乳腺癌中的荧光原位杂交（FISH）及人表皮生长因子受体2（HER2）/免疫组化结果不明确
Indian J Cancer. 2019 Apr-Jun;56(2):119-123. doi: 10.4103/ijc.IJC_333_18.
7
Study of HER2/neu status in Qatari women with breast carcinoma.卡塔尔乳腺癌女性患者的HER2/neu状态研究。
Saudi Med J. 2003 Aug;24(8):832-6.
8
Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression.子宫浆液性癌的人表皮生长因子受体2（Her2）检测：异常过表达情况报告
Gynecol Oncol Rep. 2020 Mar 16;32:100561. doi: 10.1016/j.gore.2020.100561. eCollection 2020 May.
9
[HER2/neu gene amplification as a mechanism of clonal heterogeneity in breast cancer].[人表皮生长因子受体2/神经（HER2/neu）基因扩增作为乳腺癌克隆异质性的一种机制]
Arkh Patol. 2019;81(6):49-55. doi: 10.17116/patol20198106149.
10
Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.在三级癌症中心开展的一项研究：通过荧光原位杂交评估免疫组化结果不明确的浸润性导管癌病例中的HER2/Neu状态及异常信号模式
Indian J Pathol Microbiol. 2011 Jul-Sep;54(3):532-8. doi: 10.4103/0377-4929.85087.
引用本文的文献
1
Quantification of long-term doxorubicin response dynamics in breast cancer cell lines to direct treatment schedules.定量分析乳腺癌细胞系对直接治疗方案的长期多柔比星反应动力学。
PLoS Comput Biol. 2022 Mar 31;18(3):e1009104. doi: 10.1371/journal.pcbi.1009104. eCollection 2022 Mar.
2
Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer.化疗对浸润性乳腺癌中紧密连接蛋白和钙黏蛋白表达的影响。
Exp Ther Med. 2019 Oct;18(4):3014-3024. doi: 10.3892/etm.2019.7930. Epub 2019 Aug 20.
3
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.评估局部判定为HER2阴性的乳腺癌女性患者中，局部与中心HER2检测结果的不一致率。
Cancer. 2014 Sep 1;120(17):2657-64. doi: 10.1002/cncr.28710. Epub 2014 Jun 13.
4
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry.利用质谱流式细胞术实现亚细胞分辨率的肿瘤组织高多重成像。
Nat Methods. 2014 Apr;11(4):417-22. doi: 10.1038/nmeth.2869. Epub 2014 Mar 2.
5
Tumour heterogeneity and immune-modulation.肿瘤异质性与免疫调节。
Curr Opin Pharmacol. 2013 Aug;13(4):497-503. doi: 10.1016/j.coph.2013.04.006. Epub 2013 May 7.
本文引用的文献
1
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.乳腺癌HER2检测中的基因异质性：专家组总结与指南
Arch Pathol Lab Med. 2009 Apr;133(4):611-2. doi: 10.5858/133.4.611.
2
Trastuzumab--mechanism of action and use in clinical practice.曲妥珠单抗——作用机制及临床应用
N Engl J Med. 2007 Jul 5;357(1):39-51. doi: 10.1056/NEJMra043186.
3
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775. Epub 2006 Dec 11.
4
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.由北中部癌症治疗组N9831组间辅助试验标本的当地、中心和参考实验室进行的HER2检测。
J Clin Oncol. 2006 Jul 1;24(19):3032-8. doi: 10.1200/JCO.2005.03.4744.
5
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.基因表达与化疗对淋巴结阴性、雌激素受体阳性乳腺癌女性患者的益处。
J Clin Oncol. 2006 Aug 10;24(23):3726-34. doi: 10.1200/JCO.2005.04.7985. Epub 2006 May 23.
6
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.对HER-2免疫染色为可疑(2+)的乳腺癌瘤内异质性及扩增状态的分析
Am J Clin Pathol. 2005 Aug;124(2):273-81. doi: 10.1309/J9VX-ABUG-KC4Y-07DL.
7
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.曲妥珠单抗和紫杉醇术前治疗后序贯阿霉素/环磷酰胺辅助治疗HER2过表达的II期或III期乳腺癌：一项初步研究。
J Clin Oncol. 2003 Jan 1;21(1):46-53. doi: 10.1200/JCO.2003.03.124.
8
Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.
Lab Invest. 2002 Oct;82(10):1419-26. doi: 10.1097/01.lab.0000032371.16521.40.
Zotero 插件